This indicates that while E1231 alone or in combination with NMN improves survival, the addition of the SIRT1 inhibitor EX527 does not significantly alter survival outcomes compared to the MetS group (Log-rank (Mantel-Cox) test p = 0.6). This evidence concerns the gene SIRT1 and metabolic syndrome.